Drug Development Technology: Frost & Sullivan Award goes to Imperacer
Drug Development Technology: Frost Sullivan Award goes to Imperacer
Dortmund, Germany. 29 th October 2008 – The 2008 European Immunoassay Frost Sullivan Excellence in Technology Award has been awarded to Chimera Biotec, a bioanalytical company based in Dortmund, Germany. Chimera Biotec is recognized for its pioneering Imperacer® ultra-sensitive immunoassay system, which has a 1000-fold better sensitivity compared to ELISA (Enzyme-linked Immunosorbent Assay). With a unique value proposition in the drug development and diagnostic markets, Chimera’s innovative Imperacer® products and services have experience widespread market acceptance.
“Imperacer® has a proven record for quantifying low-abundant proteins, peptides, biomarkers and a range of “difficult to quantify” markers”, says Mark Spengler, Product Manager at Chimera Biotec. “Among others Imperacer® is currently being used in fields like Alzheimer’s, rheumatoid arthritis, cardiovascular and cancer.”
Launched in 2005, Imperacer® has been successfully used in a number of applications like drug development (preclinic clinic), vaccine development, diagnostics, anti-doping testing, and proteomics. Imperacer® usually is 3 orders of magnitude more sensitive than any ELISA and is, therefore, mainly used for quantifying low abundant markers that cannot be quantified using conventional ELISA or electrochemiluminescence- technologies (ECL). Imperacer® is characterized by a broad linearity of up to 5 orders of magnitude and can be adapted to sample volumes of less than a microliter. Complementary to Imperacer®, Chimera developed a range of proprietary technologies for eliminating sample interferences (AnySource® technology) and analyte stabilization.
“After having been successfully introduced Imperacer® in research labs in 7 out of TOP 20 pharmaceutical and biotech companies in the U.S. and Switzerland we are now actively exploring broader global markets to expand our services,” states Jan Detmers, CEO of Chimera Biotec.
About Chimera Biotec
Chimera Biotec GmbH is a privately-held bioanalytical and diagnostic company based in Dortmund, Germany, that develops, manufactures, and markets ultra-sensitive immunoassays. Chimera Biotec was founded in 2000 and started marketing highly sensitive services and products in 2005. For more information please visit www.imperacer.com
Chimera Biotec Contact Information:
Mark Spengler, Ph.D.
Phone: +49-231-9742-840
Email: info@chimera-biotec.com
About Frost Sullivan
Frost Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.awards.frost.com .
Frost Sullivan Contact Information:
Joe Nivas
joe.nivas@frost.com
+44.(0).1865.398683
Drug Development Technology: Frost Sullivan Award goes to Imperacer
Dortmund, Germany. 29 th October 2008 – The 2008 European Immunoassay Frost Sullivan Excellence in Technology Award has been awarded to Chimera Biotec, a bioanalytical company based in Dortmund, Germany. Chimera Biotec is recognized for its pioneering Imperacer® ultra-sensitive immunoassay system, which has a 1000-fold better sensitivity compared to ELISA (Enzyme-linked Immunosorbent Assay). With a unique value proposition in the drug development and diagnostic markets, Chimera’s innovative Imperacer® products and services have experience widespread market acceptance.
“Imperacer® has a proven record for quantifying low-abundant proteins, peptides, biomarkers and a range of “difficult to quantify” markers”, says Mark Spengler, Product Manager at Chimera Biotec. “Among others Imperacer® is currently being used in fields like Alzheimer’s, rheumatoid arthritis, cardiovascular and cancer.”
Launched in 2005, Imperacer® has been successfully used in a number of applications like drug development (preclinic clinic), vaccine development, diagnostics, anti-doping testing, and proteomics. Imperacer® usually is 3 orders of magnitude more sensitive than any ELISA and is, therefore, mainly used for quantifying low abundant markers that cannot be quantified using conventional ELISA or electrochemiluminescence- technologies (ECL). Imperacer® is characterized by a broad linearity of up to 5 orders of magnitude and can be adapted to sample volumes of less than a microliter. Complementary to Imperacer®, Chimera developed a range of proprietary technologies for eliminating sample interferences (AnySource® technology) and analyte stabilization.
“After having been successfully introduced Imperacer® in research labs in 7 out of TOP 20 pharmaceutical and biotech companies in the U.S. and Switzerland we are now actively exploring broader global markets to expand our services,” states Jan Detmers, CEO of Chimera Biotec.
About Chimera Biotec
Chimera Biotec GmbH is a privately-held bioanalytical and diagnostic company based in Dortmund, Germany, that develops, manufactures, and markets ultra-sensitive immunoassays. Chimera Biotec was founded in 2000 and started marketing highly sensitive services and products in 2005. For more information please visit www.imperacer.com
Chimera Biotec Contact Information:
Mark Spengler, Ph.D.
Phone: +49-231-9742-840
Email: info@chimera-biotec.com
About Frost Sullivan
Frost Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.awards.frost.com .
Frost Sullivan Contact Information:
Joe Nivas
joe.nivas@frost.com
+44.(0).1865.398683